Atherosclerosis

Vascular Medicine

Volumn , Issue , 2006, Pages 101-118

  Libby, Peter ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79955034446     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0284-4.50012-9     Document Type: Chapter

References (159)

1. Ross R The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993, 362:801.
2. Libby P, Aikawa M, Schonbeck U Cholesterol and atherosclerosis. Biochim BiophysActa 2000, 1529:299.
3. Brown MS, Goldstein JL A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:232.
4. Steinberg D Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy: Part I. J Lipid Res 2004, 45:1583.
5. Steinberg D Thematic review series: The pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, Part II: The early evidence linking hypercholesterolemia to coronary disease in humans. J Lipid Res 2004, 46(2):179.
6. Oliver MF Might treatment of hypercholesterolaemia increase non-cardiac mortality?. Lancet 1991, 337:1529.
7. Moore TJ The cholesterol myth. The Atlantic Monthly 1989, 264:37.
8. Genest J, Libby P, Gotto M Lipoprotein disorders and cardiovascular disease. Heart Disease: ATextbook of Cardiovascular Medicine 2005, 1013. Elsevier, Philadelphia. 7th ed. D.P. Zipes, P. Libby, R. Bonow (Eds.).
9. Levy D, Merz CN, Cody RJ, et al. Hypertension detection, treatment and control: Acall to action for cardiovascular specialists. J Am Coll Cardiol 1999, 34:1360.
10. Gifford RW Review of the long-term controlled trials of usefulness of therapy for systemic hypertension. Am J Cardiol 1989, 63:8B.
11. Turnbull F Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003, 362:1527.
12. Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: A randomized controlled trial. JAMA 2004, 292:2217.
13. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002, 359:995.
14. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 2004, 363:2022.
15. Fuster V, Gotto AM, Libby P, et al. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: The biologic role of risk factors. J Am Coll Cardiol. 1996, 27:964.
16. McGill HC The cardiovascular pathology of smoking. Am Heart J 1988, 115:250.
17. McGill HC Smoking and the pathogenesis of atherosclerosis. Adv Exp Med Biol 1990, 273:9.
18. Celermajer DS, Sorensen KE, Georgakopoulos D, et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993, 88:2149.
19. Deanfield J Passive smoking and early arterial damage. Eur Heart J 1996, 17:645.
20. Churg A, Wang RD, Tai H, et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care Med 2003, 167:1083.
21. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486.
22. Wenger NK You've come a long way, baby: Cardiovascular health and disease in women: Problems and prospects. Circulation 2004, 109:558.
23. Stamler J The coronary drug project-findings with regard to estrogen, dextrothyroxine, clofibrate and niacin. Adv Exp Med Biol 1977, 82:52.
24. Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004, 109:672.
25. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143.
26. Genest J, Cohn J Plasma triglyceride-rich lipoprotein and high density lipoprotein disorders associated with atherosclerosis. J Invest Med 1998, 46:351.
27. Tall AR, Jiang X, Luo Y, et al. 1999 George Lyman DuffMemorial Lecture: Lipid transfer proteins, HDL metabolism, and atherogenesis. Arterioscler Thromb Vasc Biol 2000, 20:1185.
28. Navab M, Anantharamaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res 2004, 45:993.
29. Handy DE, Loscalzo J Homocysteine and atherothrombosis: Diagnosis and treatment. CurrAtheroscler Rep 2003, 5:276.
30. Ridker PM, Stampfer MJ, Rifai N Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001, 285:2481.
31. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA 2002, 288:2015. Homocysteine Studies Collaboration.
32. Wilson PW Homocysteine and coronary heart disease: How great is the hazard?. JAMA 2002, 288:2042.
33. Lowering blood homocysteine with folic acid based supplements: Meta-analysis of randomised trials. BMJ 1998, 316:894. Homocysteine Lowering Trialists' Collaboration.
34. Clarke R, Collins R Can dietary supplements with folic acid or vitamin B6 reduce cardiovascular risk? Design of clinical trials to test the homocysteine hypothesis of vascular disease. J Cardiovasc Risk 1998, 5:249.
35. Scanu AM, Nakajima K, Edelstein C Apolipoprotein(a): Structure and biology. Front Biosci 2001, 6:D546.
36. Scanu AM Lp(a) lipoprotein-coping with heterogeneity. N Engl J Med 2003, 349:2089.
37. Stein JH, Rosenson RS Lipoprotein Lp(a) excess and coronary heart disease. Arch Intern Med 1997, 157:1170.
38. Koenig W Fibrinogen and coronary risk. Curr Cardiol Rep 1999, 1:112.
39. Montalescot G, Collet JP, Choussat R, et al. Fibrinogen as a risk factor for coronary heart disease. Eur Heart J 1998, 19(Suppl H):H11.
40. Rokitansky K The organs of circulation. A Manual of Pathological Anatomy 1855, IV:201. Blanchard and Lea, Philadelphia. W.E. Swaine, C.H. Moore, E. Sieveking, G. Day (Eds.).
41. Bini A, Wu D, Schnuer J, et al. Characterization of stromelysin 1 (MMP-3), matrilysin (MMP-7), and membrane type 1 matrix metalloproteinase (MT1-MMP) derived fibrin(ogen) fragments D-dimer and D-like monomer: NH2-terminal sequences of late-stage digest fragments. Biochemistry 1999, 38:13928.
42. Libby P, Egan D, Skarlatos S Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research. Circulation 1997, 96:4095.
43. Danesh J, Collins R, Peto R Chronic infections and coronary heart disease: Is there a link?. Lancet 1997, 350:430.
44. Danesh J Coronary heart disease, Helicobacter pylori, dental disease, Chlamydia pneumoniae, and cytomegalovirus: Meta-analyses of prospective studies. Am Heart J 1999, 138:S434.
45. Danesh J, Whincup P, Lewington S, et al. Chlamydia pneumoniae IgA titres and coronary heart disease; prospective study, and meta-analysis. Eur Heart J 2002, 23:371.
46. Ridker PM Inflammation, infection, and cardiovascular risk: How good is the clinical evidence?. Circulation 1998, 97:1671.
47. Ridker PM Are associations between infection and coronary disease causal or due to confounding?. Am J Med 1999, 106:376.
48. Zhu J, Nieto FJ, Horne BD, et al. Prospective study of pathogen burden and risk of myocardial infarction or death. Circulation 2001, 103:45.
49. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: The WIZARD study: A randomized controlled trial. JAMA 2003, 290:1459.
50. Gelfand EV, Cannon CP Antibiotics for secondary prevention of coronary artery disease: An ACES hypothesis but we need to PROVE IT. Am Heart J 2004, 147:202.
51. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005, 352:1637.
52. Cannon CP, Braunwaid E, McCabe CH, et al. Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. N Engl J Med 2005, 352:1646.
53. Kalayoglu MV, Libby P, Byrne GI Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. JAMA 2002, 288:2724.
54. Libby P, Ridker PM Inflammation and atherosclerosis: Role of C-reactive protein in risk assessment. Am J Med 116 (Suppl) 2004, 6A:9S.
55. Ridker PM High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: From concept to clinical practice to clinical benefit. Am Heart J 2004, 148:S19.
56. Willerson JT, Ridker PM Inflammation as a cardiovascular risk factor. Circulation 2004, 109:112.
57. Danenberg HD, Szalai AJ, Swaminathan RV, et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003, 108:512.
58. Wang L, Fan C, Topol SE, et al. Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science 2003, 302:1578.
59. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 2004, 350:29.
60. Helgadottir A, Manolescu A, Thorleifsson G, et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 2004, 36:233.
61. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002, 32:650.
62. Ozaki K, Inoue K, Sato H, et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-alpha secretion in vitro. Nature 2004, 429:72.
63. Chobanian AV Control of hypertension-an important national priority. N Engl J Med 2001, 345:534.
64. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003, 289:2560.
65. Lenfant C, Chobanian AV, Jones DW, et al. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 2003, 41:1178.
66. Ford ES, Giles WH, Dietz WH Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287:356.
67. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001, 286:1195.
68. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003, 289:76.
69. Williams KJ, Tabas I The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 1998, 9:471.
70. Brownlee M Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813.
71. Naka Y, Bucciarelli LG, Wendt T, et al. RAGE axis: Animal models and novel insights into the vascular complications of diabetes. Arterioscler Thromb Vasc Biol 2004, 24:1342.
72. Thurberg B, Collins T The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Curr Opin Lipidol 1998, 9:387.
73. Burger PC, Wagner DD Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003, 101:2661.
74. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 2001, 107:1255.
75. Dong ZM, Brown AA, Wagner DD Prominent role of P-selectin in the development of advanced atherosclerosis in ApoE-deficient mice. Circulation 2000, 101:2290.
76. Gu L, Okada Y, Clinton S, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low-density lipoprotein-deficient mice. Mol Cell 1998, 2:275.
77. Peters W, Charo IF Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: Lessons from knockout mice. Curr Opin Lipidol 2001, 12:175.
78. Lesnik P, Haskell CA, Charo IF Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. J Clin Invest 2003, 111:333.
79. Boisvert WA, Curtiss LK, Terkeltaub RA Interleukin-8 and its receptor CXCR2 in atherosclerosis. Immunol Res 2000, 21:129.
80. Cybulsky MI, Hegele RA The fractalkine receptor CX3CR1 is a key mediator of atherogenesis. J Clin Invest 2003, 111:1118.
81. Mach F, Sauty A, Iarossi AS, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999, 104:1041.
82. Kovanen PT Role of mast cells in atherosclerosis. Chem Immunol 1995, 62:132.
83. Haley KJ, Lilly CM, Yang JH, et al. Overexpression of eotaxin and the CCR3 receptor in human atherosclerosis: Using genomic technology to identify a potential novel pathway of vascular inflammation. Circulation 2000, 102:2185.
84. Platt N, Haworth R, Darley L, et al. The many roles of the class A macrophage scavenger receptor. Int Rev Cytol 2002, 212:1.
85. Febbraio M, Hajjar DP, Silverstein RL CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001, 108:785.
86. Nicholson AC, Han J, Febbraio M, et al. Role of CD36, the macrophage class B scavenger receptor, in atherosclerosis. Ann NYAcad Sci 2001, 947:224.
87. Smith JD, Trogan E, Ginsberg M, et al. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A 1995, 92:8264.
88. Qiao JH, Tripathi J, Mishra NK, et al. Role of macrophage colony-stimulating factor in atherosclerosis: Studies of osteopetrotic mice. Am J Pathol 1997, 150:1687.
89. Rajavashisth T, Qiao JH, Tripathi S, et al. Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest 1998, 101:2702.
90. Hansson GK, Libby P, Schonbeck U, et al. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res 2002, 91:281.
91. Gerdes N, Sukhova GK, Libby P, et al. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for atherogenesis. J Exp Med 2002, 195:245.
92. Geng YJ, Libby P Progression of atheroma: A struggle between death and procreation. Arterioscler Thromb Vasc Biol 2002, 22:1370.
93. Doherty TM, Asotra K, Fitzpatrick LA, et al. Calcification in atherosclerosis: Bone biology and chronic inflammation at the arterial crossroads. Proc Natl Acad Sci U SA 2003, 100:11201.
94. Macleod MR, Amarenco P, Davis SM, et al. Atheroma of the aortic arch: An important and poorly recognised factor in the aetiology of stroke. Lancet Neurol 2004, 3:408.
95. Park AE, McCarthy WJ, Pearce WH, et al. Carotid plaque morphology correlates with presenting symptomatology. J Vasc Surg 1998, 27:872.
96. BergwerffM, Verberne ME, DeRuiter MC, et al. Neural crest cell contribution to the developing circulatory system: Implications for vascular morphology?. Circ Res 1998, 82:221.
97. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003, 348:593.
98. Shimizu K, Sugiyama S, Aikawa M, et al. Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat Med 2001, 7:738.
99. Saiura A, Sata M, Hirata Y, et al. Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nat Med 2001, 7:382.
100. Arnett EN, Isner JM, Redwood DR, et al. Coronary artery narrowing in coronary heart disease: Comparison of cineangiographic and necropsy findings. Ann Intern Med 1979, 91:350.
101. Ziada KM, Kapadia SR, Tuzcu EM, et al. The current status of intravascular ultrasound imaging. Curr Probl Cardiol 1999, 24:541.
102. Clarkson TB, Prichard RW, Morgan TM, et al. Remodeling of coronary arteries in human and nonhuman primates. JAMA 1994, 271:289.
103. Glagov S, Weisenberg E, Zarins C, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987, 316:371.
104. Strong JP, Malcom GT, McMahan CA, et al. Prevalence and extent of atherosclerosis in adolescents and young adults: Implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. JAMA 1999, 281:727.
105. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood: The Bogalusa Heart Study. JAMA 2003, 290:2271.
106. Virmani R, Robinowitz M, Geer JC, et al. Coronary artery atherosclerosis revisited in Korean War combat casualties. Arch Pathol LabMed 1987, 111:972.
107. Napoli C, D'Armiento FP, Mancini FP, et al. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J Clin Invest 1997, 100:2680.
108. Napoli C, Glass CK, Witztum JL, et al. Influence of maternal hyper-cholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 1999, 354:1234.
109. Tuzcu EM, Kapadia SR, Tutar E, et al. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: Evidence from intravascular ultrasound. Circulation 2001, 103:2705.
110. Davies PF, Polacek DC, Shi C, et al. The convergence of haemody-namics, genomics, and endothelial structure in studies of the focal origin of atherosclerosis. Biorheology 2002, 39:299.
111. Gimbrone MA, Topper JN, Nagel T, et al. Endothelial dysfunction, hemodynamic forces, and atherogenesis. Ann N Y Acad Sci 2000, 902:230.
112. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proin-flammatory cytokines. J Clin Invest 1995, 96:60.
113. Collins T, Cybulsky MI NF-kappa B: Pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 2001, 107:255.
114. Montauban van Swijndregt AD, Elbers HR, Moll FL, et al. Cerebral ischemic disease and morphometric analyses of carotid plaques. Ann Vasc Surg 1999, 13:468.
115. Falk E, Shah P, Fuster V Coronary plaque disruption. Circulation 1995, 92:657.
116. Bezerra HG, Higuchi ML, Gutierrez PS, et al. Atheromas that cause fatal thrombosis are usually large and frequently accompanied by vessel enlargement. Cardiovasc Pathol 2001, 10:189.
117. Libby P The molecular bases of the acute coronary syndromes. Circulation 1995, 91:2844.
118. Amento EP, Ehsani N, Palmer H, et al. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler ThrombVasc Biol 1991, 11:1223.
119. Galis Z, Muszynski M, Sukhova G, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994, 75:181.
120. Mach F, Schoenbeck U, Bonnefoy J-Y, et al. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40. Induction of collagenase, stromelysin, and tissue factor. Circulation 1997, 96:396.
121. Galis Z, Sukhova G, Lark M, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994, 94:2493.
122. Nikkari ST, O'Brien KD, Ferguson M, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995, 92:1393.
123. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999, 99:2503.
124. Herman MP, Sukhova GK, Libby P, et al. Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: A novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001, 104:1899.
125. Libby P, Lee RT Matrix matters. Circulation 2000, 102:1874.
126. Herman MP, Sukhova GK, Kisiel W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest 2001, 107:1117.
127. Fukumoto Y, Deguchi JO, Libby P, et al. Genetically determined resistance to collagenase action augments interstitial collagen accumulation in atherosclerotic plaques. Circulation 2004, 110:1953.
128. Farb A, Burke A, Tang A, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996, 93:1354.
129. Virmani R, Burke AP, Farb A, et al. Pathology of the unstable plaque. Prog Cardiovasc Dis 2002, 44:349.
130. Rajavashisth TB, Liao JK, Galis ZS, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999, 274:11924.
131. Slowik MR, Min W, Ardito T, et al. Evidence that tumor necrosis factor triggers apoptosis in human endothelial cells by inter-leukin-1-converting enzyme-like protease-dependent and -independent pathways. Lab Invest 1997, 77:257.
132. Sugiyama S, Kugiyama K, Aikawa M, et al. Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: Involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler ThrombVasc Biol 2004, 24:1309.
133. Barger A, Beeuwkes IR, Lainey L, et al. Hypothesis: Vasa vasorum and neovascularization of human coronary arteries. N Engl J Med 1984, 310:175.
134. Coughlin SR Sol Sherry lecture in thrombosis: How thrombin 'talks' to cells: Molecular mechanisms and roles in vivo. Arterioscler ThrombVasc Biol 1998, 18:514.
135. Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA 2004, 291:210.
136. Beckman JA, Ganz J, Creager MA, et al. Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol 2001, 21:1618.
137. Bruschke AV, Kramer J, Bal ET, et al. The dynamics of progression of coronary atherosclerosis studied in 168 medically treated patients who underwent coronary arteriography three times. Am Heart J 1989, 117:296.
138. Yokoya K, Takatsu H, Suzuki T, et al. Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis: A study based on four serial coronary arteriograms per year. Circulation 1999, 100:903.
139. Davies MJ, Woolf N, Rowles PM, et al. Morphology of the endothelium over atherosclerotic plaques in human coronary arteries. Br Heart J 1988, 60:459.
140. Davies MJ Stability and instability: The two faces of coronary atherosclerosis. The Paul Dudley White Lecture, 1995. Circulation 1996, 94:2013.
141. Faggiotto A, Ross R, Harker L Studies of hypercholesterolemia in the nonhuman primate. I. Changes that lead to fatty streak formation. Arteriosclerosis 1984, 4:323.
142. Faggiotto A, Ross R Studies of hypercholesterolemia in the non-human primate. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis 1984, 4:341.
143. Burke AP, Kolodgie FD, Farb A, et al. Healed plaque ruptures and sudden coronary death: Evidence that subclinical rupture has a role in plaque progression. Circulation 2001, 103:934.
144. Goldstein JA, Demetriou D, Grines CL, et al. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 2000, 343:915.
145. Asakura M, Ueda Y, Yamaguchi O, et al. Extensive development of vulnerable plaques as a pan-coronary process in patients with myocardial infarction: An angioscopic study. J Am Coll Cardiol 2001, 37:1284.
146. Rioufol G, Finet G, Ginon I, et al. Multiple atherosclerotic plaque rupture in acute coronary syndrome: A three-vessel intravascular ultrasound study. Circulation 2002, 106:804.
147. Libby P Act local, act global: Inflammation and the multiplicity of "vulnerable" coronary plaques. J Am Coll Cardiol 2005, 45:1600.
148. Lombardo A, Biasucci LM, Lanza GA, et al. Inflammation as a possible link between coronary and carotid plaque instability. Circulation 2004, 109:3158.
149. Libby P, Aikawa M Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat Med 2002, 8:1257.
150. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization. Circulation 1998, 97:2433.
151. Bustos C, Hernandez-Presa MA, Ortego M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998, 32:2057.
152. Hernandez-Presa MA, Bustos C, Ortego M, et al. ACE inhibitor quinapril reduces the arterial expression of NF-kappa B-dependent proinflammatory factors but not of collagen I in a rabbit model of atherosclerosis. Am J Pathol 1998, 153:1825.
153. Lutgens E, Gijbels M, Smook M, et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002, 22:975.
154. Hansson GK, Robertson AK TGF-beta in atherosclerosis. Arterioscler Thromb Vasc Biol 2004, 24:e137.
155. Aikawa M, Voglic SJ, Sugiyama S, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999, 100:1215.
156. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003, 290:2292.
157. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004, 291:1071.
158. Zhao XQ, Yuan C, Hatsukami TS, et al. Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: A case-control study. Arterioscler Thromb Vasc Biol 2001, 21:1623.
159. Libby P The forgotten majority: Unfinished business in cardiovascular risk reduction. J Am Coll Cardiol 2005, [In press].